Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GERN 
Geron Corporation (GERN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: GERN (1-star) is a SELL. SELL since 5 days. Profits (-10.63%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $3.69
1 Year Target Price $3.69
| 4 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.5% | Avg. Invested days 31 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 878.95M USD | Price to earnings Ratio - | 1Y Target Price 3.69 |
Price to earnings Ratio - | 1Y Target Price 3.69 | ||
Volume (30-day avg) 9 | Beta 0.68 | 52 Weeks Range 1.17 - 5.06 | Updated Date 07/11/2025 |
52 Weeks Range 1.17 - 5.06 | Updated Date 07/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -119.54% | Operating Margin (TTM) -42.18% |
Management Effectiveness
Return on Assets (TTM) -16.07% | Return on Equity (TTM) -45.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 642062571 | Price to Sales(TTM) 7.56 |
Enterprise Value 642062571 | Price to Sales(TTM) 7.56 | ||
Enterprise Value to Revenue 5.52 | Enterprise Value to EBITDA -9.06 | Shares Outstanding 636918016 | Shares Floating 537813355 |
Shares Outstanding 636918016 | Shares Floating 537813355 | ||
Percent Insiders 0.09 | Percent Institutions 81.22 |
Upturn AI SWOT
Geron Corporation
Company Overview
History and Background
Geron Corporation was founded in 1990. It is a late-stage clinical biopharmaceutical company focused on the development and commercialization of a first-in-class telomerase inhibitor, imetelstat, for the treatment of hematologic malignancies. They initially focused on telomerase inhibitors, but encountered setbacks before recent advancements with imetelstat.
Core Business Areas
- Hematologic Malignancies: Focuses on the development and commercialization of imetelstat for myelodysplastic syndromes (MDS) and myelofibrosis (MF).
Leadership and Structure
The leadership team includes John A. Scarlett (Chairman and CEO). The company structure is typical for a biopharmaceutical company, with research and development, clinical operations, regulatory affairs, and commercial functions.
Top Products and Market Share
Key Offerings
- Imetelstat: Imetelstat is a telomerase inhibitor being developed for myelodysplastic syndromes (MDS) and myelofibrosis (MF). It is not yet approved. If approved, competitors would include drugs from companies like Bristol Myers Squibb and Sierra Oncology (acquired by GSK).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and intense competition. Advancements in cancer research and personalized medicine are driving growth.
Positioning
Geron is positioning itself as a leader in telomerase inhibition for hematologic malignancies. Its competitive advantage lies in its first-in-class telomerase inhibitor, imetelstat.
Total Addressable Market (TAM)
The market size for MDS and MF therapies is significant and growing. Specific TAM figures depend on pricing and market penetration rates, but estimates reach billions of dollars. Geron aims to capture a substantial share with imetelstat.
Upturn SWOT Analysis
Strengths
- First-in-class telomerase inhibitor
- Promising clinical trial results for imetelstat in MDS and MF
- Strong intellectual property portfolio
Weaknesses
- Reliance on a single product (imetelstat)
- High R&D costs
- Regulatory approval risk
- No products currently generating revenue
Opportunities
- Potential approval of imetelstat for MDS and MF
- Expansion of imetelstat into other hematologic malignancies
- Partnerships and collaborations
- Further telomere research
Threats
- Clinical trial failures
- Regulatory rejection
- Competition from existing and emerging therapies
- Patent challenges
- Financial constraints
Competitors and Market Share
Key Competitors
- BMY
- GSK
Competitive Landscape
Geron's advantage is its novel telomerase inhibition mechanism. Disadvantages include being a smaller company with limited resources compared to large pharmaceutical companies like Bristol Myers Squibb and GSK.
Growth Trajectory and Initiatives
Historical Growth: Historically, Geron's growth is defined by R&D progress. Financial growth will depend on imetelstat approval and market acceptance.
Future Projections: Future growth hinges on imetelstat's approval for MDS and MF. Analyst projections vary widely based on approval expectations and market penetration.
Recent Initiatives: Recent initiatives include advancing imetelstat through clinical trials, preparing for potential regulatory submissions, and securing funding.
Summary
Geron Corporation is a high-risk, high-reward clinical-stage company. Success hinges on the approval and commercial success of imetelstat. The company's first-in-class telomerase inhibitor offers a potential breakthrough in hematologic malignancies, but faces significant regulatory and competitive hurdles. Positive clinical trial results are critical for attracting investment and driving shareholder value. It must secure approvals to be a long term player.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Company press releases
- Analyst reports
- Clinical trial data
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The information provided is based on available data and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Geron Corporation
Exchange NASDAQ | Headquaters Foster City, CA, United States | ||
IPO Launch date 1996-06-30 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 229 | Website https://www.geron.com |
Full time employees 229 | Website https://www.geron.com | ||
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.